Neoadjuvant and Adjuvant Therapy

Core Concepts & Aims - Setting the Stage

• Neoadjuvant Therapy (NAT): Systemic or local therapy administered before definitive surgery.
  • Aims: Downstage tumor, improve resectability, assess biological response, early micrometastasis control.
• Adjuvant Therapy (AT): Systemic or local therapy administered after definitive surgery.
  • Aims: Eradicate residual micrometastases, reduce recurrence risk, improve overall survival.
• Perioperative Therapy: Treatment strategy involving therapy both before and after surgery, aiming for comprehensive tumor control.

⭐ Neoadjuvant therapy provides a unique opportunity for in-vivo assessment of tumor sensitivity to specific treatments, guiding further management strategies.

Neoadjuvant Approach - Shrink Smart

Administered before definitive surgery.

• Goal: Shrink tumor (downstage), ↑ resectability, early micrometastasis control.
• Key Indications:
  • Locally advanced tumors (e.g., breast, rectal, esophageal, H&N, sarcoma).
  • Borderline resectable cases.
  • Organ preservation (e.g., breast, larynx, rectal sphincter).
• Advantages:
  • Assesses in vivo chemo/radio-sensitivity.
  • ↑ R0 resection rates.
  • Enables less radical surgery.
• Disadvantages:
  • Surgery delay.
  • Treatment toxicity.
  • Rare risk of progression.
• Modalities: Chemo (NACT), Radio (NART), CRT, Hormonal, Targeted, Immuno.

⭐ Pathological Complete Response (pCR) post-neoadjuvant therapy is a strong prognostic indicator in many cancers like breast and rectal.

Adjuvant Approach - Safety Net Strategy

• Therapy after surgery; targets micrometastases to ↓ recurrence & ↑ survival.
• Key Rationale: "Safety net" post-primary tumor removal.
• Indications:
  • High-risk pathology: positive margins, nodal spread (e.g., pN+), high grade.
  • Certain cancers (e.g., breast, colorectal, lung).
• Modalities: Chemotherapy (CTX), Radiotherapy (XRT), Hormonal, Targeted, Immunotherapy.
• Pros: Addresses occult disease; pathology-informed.
• Cons: Overtreatment risk; toxicity; potential delay.

⭐ Adjuvant therapy in Stage III colon cancer or HER2+ breast cancer is a standard of care, significantly boosting cure rates post-surgery.

Comparative Analysis - Tale of Two Timings

Tumour-Specific Protocols - Real-World Tactics

• Breast Cancer:
  • Neoadjuvant: For downstaging (e.g., LABC), HER2+ (TCHP), TNBC (AC-T ± Pembrolizumab).
  • Adjuvant: Based on receptor status & risk (e.g., Endocrine Tx, Trastuzumab, Chemo).
• Colorectal Cancer (CRC):
  • Rectal (locally advanced): Neoadjuvant Chemoradiotherapy (CRT) (e.g., Capecitabine/5-FU + RT) is standard.
  • Colon (Stage III, high-risk Stage II): Adjuvant FOLFOX or CAPOX.
• Esophageal/Gastric Cancer:
  • Adenocarcinoma (Gastric/Esophageal): Perioperative FLOT (5-FU, Leucovorin, Oxaliplatin, Docetaxel).
  • Esophageal SCC: Neoadjuvant CRT (CROSS protocol: Carboplatin/Paclitaxel + RT) or definitive CRT.
• Soft Tissue Sarcomas (High-Risk):
  • Neoadjuvant RT ± Chemo (e.g., Doxorubicin/Ifosfamide) for limb preservation, large/deep tumours. Adjuvant if upfront surgery.

⭐ For locally advanced rectal cancer, neoadjuvant chemoradiotherapy (CRT) followed by Total Mesorectal Excision (TME) is the standard of care, significantly improving local control and sphincter preservation rates.

Loading diagram…

High‑Yield Points - ⚡ Biggest Takeaways

• Neoadjuvant therapy: given before surgery to downstage tumors, improving resectability.
• Adjuvant therapy: given after surgery to target micrometastases, reducing recurrence.
• Modalities: chemotherapy, radiotherapy, hormone therapy, immunotherapy, targeted therapy.
• Indications vary by tumor type, stage, grade, and patient factors.
• Response assessment (e.g., RECIST for neoadjuvant) guides further treatment.
• Timing: Adjuvant therapy usually starts 4-6 weeks post-surgery.
• Goals: Improve disease-free survival (DFS) and overall survival (OS).